Free Trial
NASDAQ:PGNY

Progyny Q2 2025 Earnings Report

Progyny logo
$22.05 -0.96 (-4.17%)
As of 02:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Progyny EPS Results

Actual EPS
N/A
Consensus EPS
$0.42
Beat/Miss
N/A
One Year Ago EPS
N/A

Progyny Revenue Results

Actual Revenue
N/A
Expected Revenue
$315.70 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Progyny Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:45PM ET

Conference Call Resources

Progyny Earnings Headlines

Leerink Partnrs Has Bullish Estimate for Progyny Q2 Earnings
Elon’s Party Just Hit the IRS Where It Hurts
Elon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regain control, one overlooked IRS “backdoor” still allows retirement savers to protect their wealth — penalty-free and tax-free. A free 2025 guide reveals how to use it before it’s too late.
FY2026 EPS Estimates for Progyny Lifted by Leerink Partnrs
See More Progyny Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Progyny? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Progyny and other key companies, straight to your email.

About Progyny

Progyny (NASDAQ:PGNY), traded on the NASDAQ under the symbol PGNY, is a New York City–based company specializing in comprehensive fertility and family building benefits. The company partners with employers to design and administer programs that support employees through all stages of fertility treatment and family formation. By integrating clinical expertise, data analytics and personalized case management, Progyny aims to improve success rates and reduce overall costs associated with fertility care.

Progyny’s benefit offerings encompass a wide range of services, including in vitro fertilization (IVF), egg and embryo freezing, gestational carrier services, donor gametes, adoption assistance and genetic screening. The company’s model features a network of fertility specialists, digital tools for ongoing patient engagement and dedicated case managers who guide members through treatment plans. This combination of clinical oversight and data-driven insights enables employers and members to track outcomes and optimize care pathways.

Founded in the mid-2010s and publicly listed in 2020, Progyny has rapidly expanded its footprint across the United States, serving a diverse portfolio of large employers in industries such as technology, finance, retail and manufacturing. The company continually invests in research and partnerships to broaden access to cutting-edge reproductive technologies and telehealth services. Progyny’s leadership team includes seasoned executives with backgrounds in health care administration, benefits management and biotechnology, reflecting its commitment to innovation and quality in fertility care.

View Progyny Profile

More Earnings Resources from MarketBeat